Slide 1: Q3/9M 2021 Results
Q3/9M 2021 Results Matthias Gaertner, CEO Falk Neukirch, CFO November 9, 2021
Slide 2: Executive summary, Financial overview, Guidance 2021, Appendix
1 Executive summary 2 Financial overview 3 Guidance 2021 4 Appendix 2
Slide 3: Highlights Q3 2021: Ongoing & sustainable growth story
Executive summary Highlights Q3 2021: Ongoing & sustainable growth story Ongoing progress in strategy implementation • Continuous screening of M&A targets mainly with focus on compounding and digitalization Pharmaceutical Supply: • Advanced integration of Cranach Pharma: leverage synergy potentials
Slide 4: Continuous success story
Executive summary Continuous success story Revenue €m EBITDA pre¹ €m EBT pre¹ €m 354 8.6 8.6 10.0 9.5 316 319 8.8 7.1 163 160 174 4.8 4 4.3 3.7 130 3.8 3.1 2.8 2.5 2.2 margin 2.7 2.4 3.0 2.7 2.3 1.2 2.3 2.2 margin 2.3 2.0 1.6 1.9 0.9 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q1 Q2 Q3 Q4 Q1 Q2 Q3 202
Slide 5: 9M 2021 – Growth story reflected in the sustainable increase of key figures
Executive summary 9M 2021 – Growth story reflected in the sustainable increase of key figures Revenue €m EBITDA pre¹ €m EBT pre¹ €m 989 24.4 28.2 453 10.2 8.0 9M 2020 9M 2021 9M 2020 9M 2021 9M 2020 9M 2021 ¹ EBITDA and EBT without extraordinary expenses: adjusted for extraordinary expenses for stoc
Slide 6: 9M 2021 – Split by segments
Executive summary 9M 2021 – Split by segments Revenue by segment1 EBITDA pre by segment2 5% 20% 95% 80% Pharmaceutical Supply Pharmaceutical Supply Patient-specific Therapies Patient-specific Therapies ¹ External revenue excl. Services segment (€0.5m); 2 EBITDA without extraordinary expenses: adjust
Slide 7: ESG strategy well under way
Sustainability ESG strategy well under way Code of conduct published end of 2020 2021 For the first time publication of a “voluntary • Establishment of a Sustainability committee report 2020” based on CSR-RUG¹ • Nov / Dec: publication of Medios’ ESG strategy Implementation of ESG targets in the remu
Slide 8: Financial overview
1 Executive summary 2 Financial overview 3 Guidance 2021 4 Appendix 8
Slide 9: 9M 2021 – Financials
Financial overview 9M 2021 – Financials In € million 9M 2021 9M 2020 ∆% Revenue 988.8 452.9 118.3 • Strong revenue growth: inorganic (+97%), Gross profit* 26.2 organic (+22%) 49.0 87.2 gross margin in % 5.0% 5.8% • Slightly lower gross margin due to weighting effect: over-proportional increase of th
Slide 10: 9M 2021 – Revenue-bridge per segment
Financial overview 9M 2021 – Revenue-bridge per segment 9M YoY Revenue in €m 9M 2020 Organic Inorganic 9M 2021 Pharmaceutical Supply 406.0 98.6 437.1 941.7 • Almost 22% organic growth thereof Cranach Pharma 0 0 437.1 437.1 supported by synergy effects Patient-specific Therapies 46.5 -1.4 1.4 46.5 th
Slide 11: Q3 2021 – Record quarter driven by strong inorganic and organic growth
Financial overview Q3 2021 – Record quarter driven by strong inorganic and organic growth Q3 YoY Revenue in €m Q3 2020 Organic Inorganic Q3 2021 Pharmaceutical Supply 144.0 35.3 158.9 338.2 • Organic growth almost 22% thereof Cranach Pharma 0.0 0.0 158.9 158.9 • Decline in compounding revenue Patien
Slide 12: 9M 2021 – Substantial improvement of earnings margins
Financial overview 9M 2021 – Substantial improvement of earnings margins Pharmaceutical Patient-specific Internal Services and Group Supply Therapies IFRS consolidation In € million 9M 2021 9M 2020 9M 2021 9M 2020 9M 2021 9M 2020 9M 2021 9M 2020 Revenue (external) 941.7 406.0 46.5 46.5 0.5 0.3 988.8
Slide 13: Financing power - Strong financial position to invest in future growth
Financial overview Financing power- Strong financial position to invest in future growth As of Sept 30, 2021 In € million Organic growth Syndicated loan 45.9 • Remaining €2.5m of overall around €10m Thereof called -28.4 to be invested in new labs in Berlin External growth Cash & cash equivalents 81.
Slide 14: Guidance 2021
1 Executive summary 2 Financial overview 3 Guidance 2021 4 Appendix 14
Slide 15: Forecast confirmed
Guidance 2021 Forecast confirmed In € million 2021F¹ 2020 Growth % Group revenue 1,200 –1,300 626.5 92 – 107 + External growth will be substantially driven EBITDA pre² 38 – 39 15.1 152 – 159 by the acquisitions of Cranach Pharma, and margin (% of revenue) 3.2% 2.4% Koelsche Blister; additional acqui
Slide 16: Good plan for overall growth
Growth strategy Good plan for overall growth • Establish new labs in Berlin by the end of 2021– to • Ongoing M&A focusing on be able to triple manufacturing capacities • Compounding - increase in capacities for • Expand “blistering” focusing on high-priced drugs enhanced production of individualized
Slide 17: Appendix
1 Executive summary 2 Financial overview 3 Guidance 2021 4 Appendix 17
Slide 18: Key figures (1/2)
Appendix Key figures (1/2) in € thousand 9M 2021 9M 2020 ∆ in % Q3 2021 Q3 2020 ∆ in % Revenue 988,765 452,900 118.3% 353,839 160,015 121.1% Pharmaceutical Supply 941,745 406,044 131.9% 338,185 143,970 134.9% Patient-Specific Therapies 46,544 46,544 0.0% 15,498 15,940 -2.8% Services 476 312 53.1% 15
Slide 19: Key figures (2/2)
Appendix Key figures (2/2) in € thousand 9M 2021 9M 2020 ∆ in % Q3 2021 Q3 2020 ∆ in % Earnings per share (in €) Undiluted 0.50 0.28 78.6% 0.18 0.07 157.1% Diluted 0.48 0.27 77.8% 0.17 0.07 142.9% Investments (CAPEX) 8,948 3,140 185.0% 3,188 925 244.6% Cash flow from operating activities 40,359 6,94
Slide 20: Consolidated statement of comprehensive income
Appendix Consolidated statement of comprehensive income in thousand € 9M 2021 9M 2020 ∆ in % Q3 2021 Q3 2020 ∆ in % Revenue 988,765 452,900 118.3% 353,839 160,015 121.2% Change in stocks of finished goods & work-in progress 0 45 -99.7% -30 32 -195.6% Work performed and capitalized 405 17 > 1,000% 13
Slide 21: Consolidated balance sheets
Appendix Consolidated balance sheets Sep 30, Sep 30, Assets in thousand € FY 2020 ∆ in % Liabilities in thousand € FY 2020 ∆ in % 2021 2021 Non-current assets 227,013 58,232 289.9% Equity Intangible assets 198,724 35,237 464.0% Subscribed capital 20,265 16,085 26.0% Property, plant and equipment 11,
Slide 22: Consolidated cash flow statement 9M 2021 (1/2)
Appendix Consolidated cash flow statement 9M 2021 (1/2) in thousand € 9M 2021 9M 2020 ∆ in % Q3 2021 Q3 2020 ∆ in % Cash flow from operating activities Net income for the period 9,890 4,269 131.7% 3,617 1,101 228.7% Depreciation and amortization on non-current assets 11,596 2,568 351.5% 3,923 947 31
Slide 23: Consolidated cash flow statement 9M 2021 (2/2)
Appendix Consolidated cash flow statement 9M 2021 (2/2) in thousand € 9M 2021 9M 2020 ∆ in % Q3 2021 Q3 2020 ∆ in % Cash flow from investment activities Payments made for investments in intangible assets -1,949 -1,203 49.55% -946 -532 78.0% Payments from disposals of intangible assets 250 0 n/a 0 0
Slide 24: Management structure with effect from October 1
Introduction Management structure with effect from October 1 Executive Board Supervisory Board CEO CFO COO CINO1 Chairman Deputy Member Member Matthias Falk Mi-Young Christoph Dr. Yann Samson Chairman Klaus J. Buß Dr. Anke Nestler Gärtner Neukirch Miehler Prußeit Joachim Messner Audit Remuneration &
Slide 25: Contact
Contact Claudia Nickolaus Head of Investor & Public Relations Phone +49 30 232 566 800 ir@medios.ag 25
Slide 26: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C
Slide 27: Q3/9M 2021 Results
Q3/9M 2021 Results Matthias Gaertner, CEO Falk Neukirch, CFO November 9, 2021